Elevated IdoA content in tumor-associated DS enhances hepatocyte growth factor (HGF)-mediated signaling and ERK1/2 activation [61,62], a pathway that YKL-40 is also known to modulate [63,64,65]. This evidence concerns the gene MAPK3 and neoplasm.